A number of key proteins are validated drivers of proliferation and/or survival of tumor cells in many cancers with poor prognosis exhibiting limited response to standard therapy. Such proteins, including K-Ras, cMyc and PI3K are often dysregulated by chromosomal gene amplification or by gain-of-function mutations causing uncontrolled cancer cell proliferation and survival. We are devoted to the identification of novel drug candidates for key “tough-to-drug” oncogenic targets and their chaperone proteins with the ultimate goal of providing improved clinical outcomes for cancer patients. Recent clinical data within the rapidly emerging field of immuno-therapy has revealed promising results for cancer patients, and has ignited the field of Immuno-oncology.

In addition to our RORγt agonist program for immune stimulation, we have initiated the screening of multiple intracellular immune-checkpoint targets decisive in the control of immunological response to cancer cells. The goal of these projects is to provide small-molecule drugs providing improved clinical outcomes, when applied either as mono-therapy or in drug combinations.

Auto-immune diseases affect millions of patients and a large subset of these diseases like rheumatoid arthritis, psoriasis, multiple sclerosis, ankylosing spondylitis, uveitis and others originate from the dysregulation of cells of the immune systems – most notably of T cells from the TH17 lineage.

We are screening multiple cytokines, their receptors and intracellular targets, which are critical for autoimmune diseases. In doing so, we seek to identify disease-modifying drug candidates with novel mode of action and offering significant improvement over current standard-of-care for patients.

Rolling wave pipeline

Each year, we plan to screen in the order of 15 biological disease targets in the search for new breakthrough medicines offering novel and/or safer mode of actions rather than providing one more me-too copy of current treatment options.